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LONG-TERm ImPACT Of THE dUTCH COLORECTAL CANCER SCREENING 
PROGRAmmE ON CANCER INCIdENCE: ExPLORATION Of THE SERRATEd 
PATHwAy
Greuter M.J.1, Lew J.B.2, Berkhof J.1, Canfell K.2, Dekker E.3, Meijer G.A.1, Coupe V.M.1
1VU University Medical Center, Amsterdam, The Netherlands, 2University of New South Wales, 
Sydney, Australia, 3Academic Medical Center, Amsterdam, The Netherlands
Objectives: The Netherlands has recently started with the stepwise implemen-
tation of biennial faecal immunochemical testing for colorectal cancer (CRC). We 
evaluated the impact of the transition to, and the fully implemented screening pro-
gramme on the long-term CRC incidence and colonoscopy demand. MethOds: The 
previously reported and calibrated ASCCA model was set up to simulate the Dutch 
CRC screening programme between 2014 and 2044. We adopted an open-model 
approach by simulating multiple birth cohorts and combining the results while 
accounting for the ageing of the population. Besides a no screening scenario, we 
evaluated the impact of screening under three sets of natural history assumptions 
which differed in the contribution of the serrated pathway to the CRC incidence 
(0%, 15% and 30%). Model-predicted outcomes were CRC incidence and colonoscopy 
demand per year. Results: Due to ageing, the model-predicted CRC incidence in 
the no screening scenario increased from 77/100,000 in 2014 to 109/100,000 in 2044. 
Under screening, the predicted CRC incidence in 2014 was between 105/100,000 
(assuming all CRCs originate from adenomas) and 109/100,000 (assuming that 30% of 
CRCs arises from serrated lesions) due to the detection of asymptomatic, prevalent 
tumours. After this peak, the predicted incidence gradually decreased until in 2039 a 
new equilibrium was reached, ranging between 65/100,000 and 71/100,000 assuming 
that 100% versus 70% of CRCs originate from adenomas, respectively. Due to the 
stepwise implementation, the predicted number of colonoscopies required for the 
screening programme increased gradually over time from 38,000 (752,199 invitees) 
in 2014 to 117,000 (2,154,875 invitees) in 2044. cOnclusiOns: The Dutch screening 
programme will markedly decrease CRC incidence in the next 25 years. The conclu-
sions about the impact of screening were robust to key natural history assumptions. 
With the results of this study, decision-makers can anticipate the expected change 
in CRC-related health care use and colonoscopy demand.
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PRImARy TREATmENTS fOR INTERmEdIATE-RISk PROSTATE CANCER: A COST-
EffECTIvENESS ANd vALUE-Of-INfORmATION ANALySIS
Piena M.1, IJzerman M.J.2, Steuten L.M.G.3
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Objectives: Intermediate-risk prostate cancer patients are recommended pri-
mary treatment with either radical prostatectomy (RP), external beam radio-
therapy (EBRT), brachytherapy (BT), or EBRT plus high-dose rate BT boost (EBRT 
+ HDR-BT); or expectant management with active surveillance (AS). The costs 
of these treatments differ considerably, whilst the amount and quality of evi-
dence for their comparative effectiveness in terms of disease progression, 
adverse events and health-related quality of life is unbalanced and inconclusive. 
Therefore, we undertook a cost-effectiveness analysis of RP, EBRT, BT, EBRT + 
HDR-BT and AS, and performed a value-of-information analysis to direct future 
research. MethOds: We developed a probabilistic Markov model estimating the 
expected incremental cost/(Quality Adjusted) Life Years from a UK-NHS perspec-
tive, with a time horizon of 10 years. Input data were obtained from the best 
available literature. We explored the uncertainty around the model outcomes by 
identifying the most influential parameters and estimating the expected value 
of perfect (parameter) information. Results: AS is most likely to be cost-effec-
tive at a cost/QALY threshold (λ ) < ₤3,000/QALY, BT for λ ₤3,000 to ₤12,000/QALY 
and RP for λ > ₤12,000/QALY. One-way sensitivity analysis shows that utilities 
and probabilities of adverse events are main effect drivers and initial treatment 
costs are main cost drivers. Large decision uncertainty exists around λ ₤11,000 
with a population EVPI of nearly ₤100 million. The EVPPI suggests that eliminat-
ing uncertainty around costs and utilities is most worthwhile. cOnclusiOns: 
With current information AS and BT are cost-effective treatments for 
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intermediate-risk prostate cancer at relatively low cost/QALY thresholds, 
and RP is expected to be the most cost-effective of available treatments at the 
prevailing range of cost/QALY thresholds (i.e. ₤20,000-₤30,000) . However, large 
decision uncertainty exists and acquiring further information is likely cost-effec-
tive. Future research on costs and utilities associated with treatment outcome and 
adverse events is expected to be most valuable.
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EARLy STAGE COST-EffECTIvENESS ANALySIS Of A BRCA1-LIkE TEST TO 
dETECT TRIPLE NEGATIvE BREAST CANCERS RESPONSIvE TO HIGH dOSE 
ALkyLATING CHEmOTHERAPy
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Objectives: Triple negative breast cancers (TNBC) with a BRCA1-like profile may 
benefit from high dose alkylating chemotherapy (HDAC). This study examines 
whether treating TNBC with personalized HDAC based on BRCA1-like testing can 
be more cost-effective than current clinical practice. Additionally we estimated 
the minimum required prevalence of BRCA1-likeness and the required positive 
predictive value (PPV) for a BRCA1-like test to render this strategy cost-effec-
tive. MethOds: Our markov model compared the outcomes of treating TNBC 
women with personalized HDAC based on BRCA1-like testing vs. current clinical 
practice from a societal Dutch perspective and a 20-year time horizon. From our 
base-case model we assessed: 1) the incremental number of respondents; 2) the 
incremental number of Quality Adjusted Life Years, 3) the incremental costs, and 
4) the incremental cost-effectiveness ratio (ICER). We performed one-way sensi-
tivity analysis (SA) of all model parameters, and two-way SA of prevalence and 
PPV. Data were obtained from a current trial (NCT01057069), published literature 
and expert opinions where necessary. Results: Based on our base-case analysis 
with 68% BRCA1-like prevalence, 100% PPV, and costs of € 164 / test, treating TNBC 
according to BRCA1-like testing would be cost-effective (€ 16.192/QALY). One-way 
SA on the prevalence and PPV demonstrated that only the PPV drives the ICER 
changes. In two-way SA, the lower bound for the two parameters was: prevalence 
39.6% and PPV 46.4%. Regardless of prevalence, at PPVs > 46.4% BRCA1-like testing 
was always cost-effective. cOnclusiOns: Treating TNBC with personalized HDAC 
based on BRCA1-like testing is expected to be cost-effective at a minimum PPV of 
46%. This information can help test developers in decisions on further research 
and development.
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THE COST Of COSTING TREATmENTS INCORRECTLy: ERRORS IN THE 
APPLICATION Of dRUG PRICES IN ECONOmIC mOdELS dUE TO dIffERING 
PATIENT wEIGHTS
Hatswell A.J.1, Porter J.1, Hertel N.2, Lee D.1
1BresMed, Sheffield, UK, 2Bristol Myers Squibb, Uxbridge, UK
Objectives: Drug costs are generally a key driver of the results of economic models. 
We tested the impact on drug cost estimates for the following common approaches: 
using mean patient weight, individual patient weights or fitting a distribution to the 
observed patient weights. MethOds: For the analysis, we utilised patient weight 
and height data from trial CA184-024 (517 patients) in metastatic melanoma. Based 
on this dataset, costs of a single administration of drug therapy were calculated 
using UK list prices. Costs were calculated for four recently licensed treatments 
with different posologies: ipilimumab (mg/kg, with 2 vial sizes), cabazitaxel (mg/
m2), ustekinumab (doubled dosage over 100kg patient weight) and romiplostim (µg/
kg, with a large, single vial size). Results: Cost estimates using the mean patient 
weight were £18,750, £3,696, £2,147 and £482 per administration of ipilimumab, 
cabazitaxel, ustekinumab and romiplostim, respectively. These results increased 
by 4.9%, 2.3%, 10.3% and 36.6% when costing individual patient weights, and by 
5.2%, 2.3%, 11.8% and 36.9% when fitting a distribution to the patient weights. The 
use of only mean patient weight consistently underestimated costs compared to 
methods that incorporated the distribution of weight data. Sampling from the 
observed patient weight distribution provides a more accurate estimation of costs; 
however, it is subject to over- or under-estimation, depending on enrolment in 
a trial programme, particularly amongst patients who are substantially over- or 
under-weight. cOnclusiOns: Accurate estimation of drug costs requires an under-
standing of the distribution of patient weights. Failing to take this into account can 
result in cost estimates that are substantially lower than will be seen in practice, 
which could (in turn) impact treatment (implementation) decisions. These errors 
would be further compounded should drug wastage not be adequately captured. 
Modellers should be mindful of these issues when costing therapies or conducting 
health technology assessment submissions.
